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Abstract
Background: In this study, we examined the effect of oxidative stress on cellular energy metabolism and pro-
angiogenic/pro-inflammatory mechanisms of primary rheumatoid arthritis synovial fibroblast cells (RASFC) and
human umbilical vein endothelial cells (HUVEC).
Methods: Primary RASFC and HUVEC were cultured with the oxidative stress inducer 4-hydroxy-2-nonenal (4-HNE),
and extracellular acidification rate, oxygen consumption rate, mitochondrial function and pro-angiogenic/pro-
inflammatory mechanisms were assessed using the Seahorse analyser, complex I–V activity assays, random mutation
mitochondrial capture assays, enzyme-linked immunosorbent assays and functional assays, including angiogenic
tube formation, migration and invasion. Expression of angiogenic growth factors in synovial tissue (ST) was assessed
by IHC in patients with rheumatoid arthritis (RA) undergoing arthroscopy before and after administration of tumour
necrosis factor inhibitors (TNFi).
Results: In RASFC and HUVEC, 4-HNE-induced oxidative stress reprogrammed energy metabolism by inhibiting
mitochondrial basal, maximal and adenosine triphosphate-linked respiration and reserve capacity, coupled with the
reduced enzymatic activity of oxidative phosphorylation complexes III and IV. In contrast, 4-HNE elevated basal
glycolysis, glycolytic capacity and glycolytic reserve, paralleled by an increase in mitochondrial DNA mutations and
reactive oxygen species. 4-HNE activated pro-angiogenic responses of RASFC, which subsequently altered HUVEC
invasion and migration, angiogenic tube formation and the release of pro-angiogenic mediators. In vivo markers of
angiogenesis (vascular endothelial growth factor, angiopoietin 2 [Ang2], tyrosine kinase receptor [Tie2]) were
significantly associated with oxidative damage and oxygen metabolism in the inflamed synovium. Significant
reduction in ST vascularity and Ang2/Tie2 expression was demonstrated in patients with RA before and after
administration of TNFi.
Conclusions: Oxidative stress promotes metabolism in favour of glycolysis, an effect that may contribute to
acceleration of inflammatory mechanisms and subsequent dysfunctional angiogenesis in RA.
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Background
Angiogenesis is one of the earliest events in the de-
velopment of rheumatoid arthritis (RA). New blood
vessels invade the synovial membrane, resulting in a
self-perpetuating and persistent infiltration of immune
cells into the joint, transforming the synovial tissue
(ST) into an aggressive, tumour-like ‘pannus’ [1]. New
capillaries also facilitate the delivery of sufficient oxy-
gen and nutrients to support the proliferating syno-
vium. Although angiogenesis is a prominent feature
of RA, the neovascular network is dysfunctional and
fails to restore tissue oxygen homeostasis, rendering
the inflamed ST hypoxic. The increase in metabolic
turnover of the expanding synovial pannus outpaces
the oxygen supply, resulting in a demand for adeno-
sine triphosphate (ATP) and an altered regulation of
cellular metabolic mechanisms [2, 3].
Bioenergetics is fundamentally important for all cells
to enable proliferation, differentiation and maturation,
with mitochondria being central to biosynthetic and
bioenergetic pathways mediated by the tricarboxylic acid
(TCA) cycle. Thus, alterations to mitochondrial respir-
ation can play a key role in mediating pathogenic mech-
anisms in chronic inflammatory diseases [4–6]. One
well-known example of mitochondrial dysfunction is the
bioenergetic switch in cell metabolism from oxidative
phosphorylation (OXPHOS) towards aerobic glycolysis,
known as the Warburg effect. Although the efficiency of
ATP production per molecule of glucose is much lower
through glycolysis, the yield rate is much faster than that
of OXPHOS, supporting rapid cellular growth. It has
been demonstrated that the Warburg effect is present in
highly proliferating and metabolically active immune
cells in a manner similar to that observed in tumour
cells. In the inflamed joint, an increase in the metabolic
state towards glycolysis has been shown in primary
rheumatoid arthritis synovial fibroblasts (RASFC), CD4
T cells, T-helper type 17 (TH17) cells, macrophages and
dendritic cells [7–10]. This is paralleled by elevated lac-
tate levels and diminished glucose in RA synovial fluids
as well as by increased activity of key glycolytic enzymes
in the RA synovium, indicating that anaerobic glycolysis
is favoured in this hypoxic environment [11–13]. More
recently, in vitro studies by our group have shown that
hypoxia and Toll-like receptor 2 (TLR2)-induced inflam-
mation promoted mitochondrial dysfunction and oxida-
tive stress and reprogrammed the nature of cellular
respiration in RA synovial cells [14, 15].
Oxidative damage occurs through the detrimental effect
of hypoxia and is recognised as an important source of gen-
omic instability that leads to respiratory alterations. Hyp-
oxia promotes overproduction of reactive oxygen species
(ROS) that provoke oxidation of polyunsaturated fatty acids
in plasma and mitochondrial membranes. This generates
an array of primary lipid peroxidation products, which sub-
sequently decompose and form reactive lipid electrophiles,
among which 4-hydroxy-2-nonenal (4-HNE) is the most
important signalling molecule [16]. 4-HNE can form cova-
lent adducts with DNA, phospholipids and nucleophilic
amino acids, impairing their structure and biological prop-
erties. In particular, mitochondria have been reported as a
prominent target of 4-HNE activity [17]. Mitochondrial
proteins related to mitochondrial energy metabolism, such
as adenosine triphosphate synthase subunit β (ATP5B), suc-
cinate dehydrogenase flavoprotein subunit and reduced
form of nicotinamide adenine dinucleotide (NADH) de-
hydrogenase iron–sulphur protein 2 in the electron trans-
port chain (ETC), and trifunctional enzyme subunit α in
the TCA cycle, are highly susceptible to 4-HNE-induced in-
activation [18–20]. A recent study has also demonstrated
4-HNE-induced inhibition of sirtuin 3, a major mitochon-
drial nicotinamide adenine dinucleotide (NAD+)-dependent
deacetylase, with subsequent up-regulation of vascular
endothelial growth factor (VEGF) expression by breast can-
cer cells [21], indicating a close connection between oxida-
tive stress, mitochondrial function and angiogenesis.
In previous studies, our group assessed levels of syn-
ovial lipid peroxidation in patients with RA and demon-
strated a significant inverse correlation between 4-HNE
expression and oxygen tension in the inflamed joint,
reflecting mitochondrial damage [22]. Subsequently, we
have demonstrated that high synovial lipid peroxidation
positively correlated with clinical disease activity scores,
and we have reported reduced 4-HNE levels in patients
with RA who responded to tumour necrosis factor
(TNF) blocking therapy corresponding with a significant
increase in partial oxygen pressure in synovial tissue, in-
dicating a reduction in synovial oxidative stress as the
joint tissue becomes less hypoxic [23]. In addition, it was
observed that increased synovial inflammation and
angiogenesis was associated with higher oxidative stress
[22]. Given the important role of mitochondrial metab-
olism in the regulation of inflammatory and angiogenic
responses, in this study we investigated the effect of
oxidative stress on the mitochondrial bioenergetic profile
and the pro-angiogenic/pro-inflammatory mechanisms
in RASFC and human umbilical vein endothelial cells
(HUVEC). Furthermore, we determined the effects of
tumour necrosis factor α inhibitors (TNFi) on the
expression of angiogenic markers in RA in relation to
synovial oxidative stress in vivo.
Methods
Patient recruitment, arthroscopy and sample collection
Fifteen patients with active RA were recruited from the
Rheumatology Department of St. Vincent’s University
Hospital, Dublin, Ireland. All patients gave fully in-
formed written consent approved by the institutional
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ethics committee, and the research was performed in
accordance with the Declaration of Helsinki. Clinical
disease activity was assessed with the 28-joint Disease
Activity Score (DAS28) using the C-reactive protein
level. Under local anaesthesia, all patients with RA
underwent arthroscopy of the inflamed knee joint prior
to biologic treatment (T0) and a second arthroscopy 3
months after commencement of TNFi (T3). ST biopsies
were used for isolation of primary synovial fibroblasts
and histological analyses.
RASFC culture
RASFC biopsies obtained at arthroscopy were digested
with 1 mg/ml collagenase type I (Worthington Biochem-
ical, Lakewood, NJ, USA) in Gibco RPMI 1640 medium
(Thermo Fisher Scientific, Paisley, UK) for 4 hours at
37 °C in humidified air with 5% CO2. Dissociated cells
were plated in RPMI 1640 medium supplemented with
10% Gibco FCS (Thermo Fisher Scientific), 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (Thermo
Fisher Scientific), penicillin (100 U/ml), streptomycin
(100 U/ml) and amphotericin B (Fungizone 0.25 μg/ml;
(Invitrogen, Plymouth, MN, USA). Cells were grown to
confluence and used between passages 4 and 7. RASFC
were seeded onto 96-well plates and into T25 flasks and
cultured in the presence of 4-HNE (2.5 μM; Cayman
Chemical, Ann Arbor, MI, USA), a highly reactive end
product of lipid peroxidation or vehicle basal medium
(0.1% ethanol). The concentration of 4-HNE used in the
experiments was based on a cell viability assay and pre-
viously published studies [24]. Following stimulation, the
effect of amplified oxidative stress on mitochondrial
function, cellular metabolism and angiogenic responses
was assessed as described below.
HUVEC culture
HUVEC (Lonza, Walkerville, MD, USA) were incubated
in MCDB (Thermo Fisher Scientific) supplemented with
L-glutamine (Thermo Fisher Scientific), 0.5 ml epidermal
growth factor (Thermo Fisher Scientific), 50 ml FCS
(Thermo Fisher Scientific), 0.5 ml of hydrocortisone, peni-
cillin (100 U/ml; Bioscience), streptomycin (100 U/ml;
Bioscience) and Fungizone (0.25 μg/ml; Bioscience). Cells
were cultured at 37 °C in humidified air with 5% CO2 and
harvested with trypsin-ethylenediaminetetraacetic acid
(Lonza). Cells were used between passages 20 and 30.
Oxygen consumption rate and extracellular acidification
rate measured using Seahorse technology
Oxygen consumption rate (OCR) and extracellular acid-
ification rate (ECAR), reflecting OXPHOS and glycolysis,
respectively, were measured before and after treatment
with oligomycin (2 μg/ml), trifluorocarbonylcyanide phe-
nylhydrazone (FCCP; 5 μM), antimycin A (2 μM) and 2-
deoxyglucose (2-DG; 25 mM) using the Seahorse XF24
analyser (Agilent Technologies, Santa Clara, CA, USA).
RASFC and HUVEC were seeded at 30,000 cells per well
in a Seahorse XF96 cell culture microplate (Agilent
Technologies) and allowed to adhere for 24 hours. Cells
were rinsed with assay medium (unbuffered DMEM sup-
plemented with 10 mM glucose, 1 mM sodium pyruvate
and 2 mM L-glutamine, pH 7.4) before incubation with
assay medium for 30 minutes at 37 °C in a non-CO2 in-
cubator. Following incubation, cells were stimulated with
4-HNE (2.5 μM) and vehicle basal medium for 2 hours.
Four baseline OCR and ECAR measurements were ob-
tained over 28 minutes before injection of specific meta-
bolic inhibitors. Moreover, to challenge the metabolic
capacity of the RASFC and HUVEC, three OCR and
ECAR measurements were obtained over 15 minutes fol-
lowing injection with oligomycin, FCCP, antimycin A
and 2-DG.
In vitro mitochondrial dysfunction and mitochondrial
DNA mutagenesis
ROS production was assessed using the DCFDA Cellular
Reactive Oxygen Species Detection Assay Kit (Abcam,
Cambridge, UK). RASFC were seeded into clear-bottomed,
dark-sided 96-well plates at a density of 2.5 × 104 cells/well
and allowed to attach overnight. Cells were washed in 1×
buffer and stained with 25 μM 2′,7′-dichlorofluorescin
diacetate in 1× buffer for 45 minutes at 37 °C and 5% CO2.
After staining, cells were washed, treated with 4-HNE and
incubated at 37 °C in 5% CO2. ROS fluorescence signal was
measured using the SpectraMax Gemini system (Molecular
Devices, Sunnyvale, CA, USA) with excitation and emission
wavelengths of 485 nm and 538 nm, respectively. Mean
fluorescence values from four wells for each condition were
obtained. To characterise the frequencies of random muta-
tions in RASFC exposed to 4-HNE for 24 hours, we used a
mitochondrial random mutation capture assay.
Mitochondrial DNA (mtDNA) was extracted using a
previously reported protocol [25]. Following extraction,
10 μg of mtDNA was digested with 100 U of TaqαI
restriction enzyme (New England Biolabs, Ipswich, MA,
USA), 1× bovine serum albumin, and a TaqαI-specific
digestion buffer (10 mM Tris HCl, 10 mM MgCl2,
100 mM NaCl, pH 8.4) for 10 hours, with 100 U of TaqαI
added to the reaction mixture every hour. PCR
amplification was performed in 25-μl reaction mixtures
containing 12.5 μl of 2× SYBR Green Brilliant Master Mix
(Stratagene, La Jolla, CA, USA), 0.1 μl of uracil DNA gly-
cosylase (New England Biolabs), 0.7 μl of forward and re-
verse primers (10 pM/μl; Integrated DNA Technologies,
Skokie, IL, USA), and 6.7 μl of H2O. The samples were
amplified using a Roche LightCycler 480 Instrument
(Roche Diagnostics, Indianapolis, IN, USA), according to
the following protocol; 37 °C for 10 minutes, 95 °C for 10
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minutes, followed by 45 cycles of 95 °C for 15 seconds
and 60 °C for 1 minute. Samples were kept at 72 °C for 7
minutes and following melting-curve analysis were imme-
diately stored at − 80 °C. The primer sequences used were
as follows: for mtDNA copy number, 5′-ACAGTTTATG
TAGCTTACCTCC-3′ (forward) and 5′-TTGCTGCG
TGCTTGATGCTTGT-3′ (reverse); for random muta-
tions, 5′-CCTCAACAGTTAAATCAACAAAACTGC-3′
(forward) and 5′-GCGCTTACTTTGTAGCCTTCA-3′
(reverse).
Examination of mitochondrial complexes I–V activity
Mitochondrial complexes I–V OXPHOS activity assay
kits (Abcam) were used to screen the direct effect of
4-HNE on all complexes of the mitochondrial respira-
tory chain. These assays are performed using whole
bovine heart mitochondria, a rich source of OXPHOS
complexes. The activity of mitochondrial complexes
I–V was measured as per the manufacturer’s instruc-
tions. Briefly, OXPHOS complex I (NADH ubiquin-
one oxidoreductase) catalyses electron transfer from
NADH to the electron carrier, ubiquinone, concomi-
tantly pumping protons across the inner mitochon-
drial membrane. The progression of this reaction was
monitored following the oxidation as a decrease in
absorbance at optical density (OD) 340 nm. OXPHOS
complex II (succinate-coenzyme Q reductase) cataly-
ses electron transfer from succinate to the electron
carrier, ubiquinone. The product, ubiquinol, is used
by complex III in the respiratory chain, and fumarate
is necessary to maintain the TCA cycle. The produc-
tion of ubiquinol in the presence of 4-HNE was mon-
itored at OD 600 nm. To examine OXPHOS complex
III activity, succinate (electron donor of complex II)
and oxidised cytochrome c (electron acceptor of com-
plex III) were added to the mitochondria to start the
electron transfer reaction that takes place during
OXPHOS.
The rate of coupled complex II + III reaction was mea-
sured by monitoring the conversion of oxidised cyto-
chrome c into reduced form, observed as an increase in
absorbance at OD 550 nm. OXPHOS complex IV (cyto-
chrome c oxidase) transfers electrons from reduced
cytochrome c to molecular oxygen and concomitantly
pumps protons across the inner mitochondrial mem-
brane. The progression of this reaction was monitored
following the oxidation as a decrease in absorbance at
OD 550 nm. OXPHOS complex V makes about 95% of a
cell’s ATP using energy generated by the proton-motive
force and can also function in the reverse direction in
the absence of a proton-motive force, hydrolysing ATP
to generate adenosine diphosphate (ADP) and inorganic
phosphate. The production of ADP by ATP synthase can
be coupled to the oxidation of NADH to NAD+, and the
progress of the coupled reaction in the presence of 4-
HNE was monitored as a decrease in absorbance at OD
340 nm. Results were calculated using SoftMax Pro 5.3
microplate analysis software (Molecular Devices). The
activity of complexes I, II, IV and V is proportional to
the decrease in absorbance, and the linear rate of reduc-
tion in absorbance over time was calculated. The activity
of complex III is proportional to the increase in absorb-
ance, and the linear rate of increase in absorbance over
time was calculated. For each complex, results are
graphically demonstrated as the percentage of enzymatic
activity in the presence of 4-HNE relative to the percent-
age of basal activity.
Quantification of pro-angiogenic mediators in RASFC
To assess the effects of oxidative stress on secretion of
VEGF, angiopoietin 2 (Ang2), platelet-derived growth
factor subunit B (PDGF-B), basic fibroblast growth fac-
tor (bFGF), interleukin (IL)-8, regulated on activation,
normal T cell expressed and secreted (RANTES) and
intercellular adhesion molecule (ICAM), RASFC were
seeded into 96-well plates. Confluent RASFC were
serum-starved for 24 hours and then cultured with 4-
HNE for 24 hours. Supernatants were harvested, and
protein secretion levels were quantified using MSD as-
says (Meso Scale Discovery, Rockville, MD, USA) or spe-
cific enzyme-linked immunosorbent assays (ELISAs)
(R&D Systems, Minneapolis, MN, USA).
Induction of pro-angiogenic mechanisms of HUVEC in
response to oxidative stress-activated RASFC
To examine if oxidatively activated RASFC could further
affect pro-angiogenic mechanisms of HUVEC, RA fibro-
blast cells were stimulated with 4-HNE for 24 hours,
and conditioned media (CM) were harvested. As a basal
medium, we used fibroblast-conditioned media from
RASFC cultured in the absence of 4-HNE. Next, the cul-
ture of HUVEC was supplemented with 10% fibroblast-
conditioned media. To ensure that the effects on
HUVEC function were not due to residual 4-HNE in the
10% fibroblast-conditioned media, HUVEC were also
cultured with RPMI 1640 medium containing 4-HNE at
the same concentration (0.25 μM), which is the same
concentration as that in the 10% RASFC CM. Following
24-hour exposure of HUVEC to fibroblast-conditioned
media, pro-angiogenic responses of endothelial cells
were assessed as described in the subsections that
follow.
HUVEC transwell invasion chambers
BD BioCoat Matrigel invasion chambers (BD Biosciences,
Wokingham, UK) were used to examine HUVEC invasion.
Cells were seeded at a density of 2.5 × 104 per well in the
migration chamber on 8-μm membranes pre-coated with
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Matrigel. HUVEC media containing 10% fibroblast-
conditioned media was placed in the lower well of the
chamber, and cells were allowed to migrate for 48 hours.
Non-migrating HUVEC were removed from the upper
surface by gentle scrubbing. Cells that had invaded were
attached to the lower membrane and fixed with 4% para-
formaldehyde (PFA) and stained with 0.1% crystal violet.
To assess the average number of invading HUVEC, cells
were counted in five random high-power fields.
HUVEC tube formation
Matrigel (50 μl; BD Biosciences, San Jose, CA, USA) was
plated in 96-well culture plates after thawing on ice and
allowed to polymerise for 30 minutes at 37 °C in humidi-
fied air with 5% CO2. HUVEC were removed from culture,
trypsinised and resuspended at a concentration of 4 × 104
cells/ml in endothelial cell growth medium. Five hundred
microliters of cell suspension was added to each chamber
in the presence of 10% fibroblast-conditioned media and
cultured for 8 hours. The tube analysis was determined
from five sequential fields (magnification × 10) with a
focus on the surface of the Matrigel by two blinded ob-
servers and a connecting branch between two discrete
endothelial cells was counted as 1 tube.
HUVEC wound repair assay
HUVEC were seeded onto 24-well plates and grown to
confluence. A single scratch wound was induced through
the middle of each well with a sterile pipette tip. Cells were
subsequently stimulated for 24 hours with 10% fibroblast-
conditioned media. HUVEC migration across the wound
margins from 8 hours was assessed and photographed
using a phase-contrast microscope. Semi-quantitative ana-
lysis of cell repopulation of the wound was assessed. Briefly,
images of the scratch wound assays were taken at × 10
magnification. The mean closure of the wound was manu-
ally calculated from the average of three individual mea-
surements from each wound. This process was repeated for
all technical replicates. Measurement of scratches at time 0
were designated as 100% open. From this, the percentage of
closure for all scratches was calculated.
HUVEC proliferation
A crystal violet cell proliferation assay was used to assess
HUVEC proliferation in the presence of RASFC-
conditioned media. HUVEC were seeded into 96-well
culture plates at a density of 5000 cells/well and left
overnight at 37 °C and 5% CO2. Next, cells were stimu-
lated with 10% fibroblast-conditioned media for 24 hours.
Following cell culture, cells were washed with PBS, fixed
in 4% PFA and stained with 1% crystal violet solution.
Plates were washed with tap water and then dried
overnight. Cells were resuspended in 1% Triton X-100
solution (Sigma-Aldrich, St. Louis, MO, USA), and cell
number was measured with a microplate reader at a
wavelength of 550 nm.
Quantification of pro-angiogenic mediators in HUVEC
HUVEC were seeded into 96-well plates and left over-
night at 37 °C and 5% CO2. The following day, cells were
stimulated with 10% fibroblast-conditioned media for
24 hours. Next, supernatants were harvested, and pro-
tein secretion levels of Ang2 and PDGF-B were quanti-
fied by using a specific ELISA (R&D Systems).
Immunofluorescence staining of RASFC and synovial
tissue
Single-immunofluorescence staining was performed on
RASFC following 24-hour cell stimulations with 4-HNE.
To visualise immunoexpression of VEGF, cells were fixed
in 4% PFA and stained with primary rabbit antibody against
VEGF (Abcam). To demonstrate ST co-expression of
markers of angiogenesis, oxidative stress and bioenergetics,
dual-immunofluorescence staining was performed on cryo-
stat synovial sections. ST sections were fixed with acetone
for 10 minutes and co-incubated with primary mouse anti-
body against human 4-HNE (GENTAUR, Kampenhout,
Belgium) and with primary rabbit antibodies against VEGF,
Ang2, Tie2, ATP5B and glucose transporter 1 (GLUT1) (all
from Abcam), glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Trevigen, Gaithersburg, MD, USA) and pyru-
vate kinase isozyme 2 (PKM2) (Abgent, San Diego, CA,
USA). Following overnight incubation in a humidified
chamber, RASFC and ST samples were incubated with
Invitrogen Alexa Fluor 488-conjugated goat Invitrogen
Superclonal™ anti-mouse secondary antibody (Thermo
Fisher Scientific) and Cy™3–conjugated goat anti-
rabbit secondary antibody (Jackson ImmunoResearch,
West Grove, PA, USA) for 60 minutes and counterstained
with 4′,6-diamidino-2-phenylindole (DAPI) nuclear stain
(Sigma-Aldrich) for 10 minutes. Samples were mounted
with Molecular Probes antifade mounting medium
(Thermo Fisher Scientific) and assessed by immunofluor-
escence microscopy (Olympus BX51; Olympus, Hamburg,
Germany).
IHC and scoring of synovial tissue
IHC was performed using 7-μm cryostat ST sections
and the DAKO ChemMate EnVision kit (Dako/Agi-
lent Technologies, Glostrup, Denmark). Sections were
defrosted at room temperature for 20 minutes, fixed
in acetone for 10 minutes and washed in PBS for 5 mi-
nutes. Non-specific binding was blocked using 1% casein
in PBS for 20 minutes. The sections were incubated with
rabbit monoclonal primary antibodies against human
VEGF, Ang2, Tie2, ATP5B (all from Abcam), GAPDH
(Trevigen) and mouse monoclonal antibodies against hu-
man 4-HNE (GENTAUR). Immunoglobulin G control
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antibodies were used as negative controls. Following 1-
hour incubation with primary antibody, endogenous per-
oxidase activity was blocked using 0.3% hydrogen perox-
ide for 5 minutes. Slides were incubated for 30 minutes
with secondary antibody/horseradish peroxidase (Dako/
Agilent Technologies). 3,3'-Diaminobenzidine (1:50) was
used to visualise staining, and Mayer’s haematoxylin
(BDH Laboratories, Poole, UK) was incubated for 30 sec-
onds as a counterstain prior to mounting in DPX mount-
ing media. Slides were scored separately for lining layer
(LL), sublining layer (SL) and vascular region (BV) using a
well-established and validated semi-quantitative scoring
method [26], where the percentage of cells that were posi-
tive for a specific marker was compared with the percent-
age of cells that were negative. Percentage positivity was
graded using a 0–4 scale, where 0 = no stained cells, 1 =
1–25%, 2 = 25–50%, 3 = 50–75 and 4 = 75–100% stained
cells. Images were captured using an Olympus DP50 light
microscope and AnalySIS software (Olympus Soft Imaging
Solutions, Lakewood, CO, USA).
Statistical analysis
IBM SPSS Statistics version 20 for Windows software
(IBM, Armonk, NY, USA) was used for statistical ana-
lysis. Wilcoxon’s signed-rank test, Spearman’s rank-
correlation coefficient and the Mann-Whitney U test
were used for analysis of non-parametric data. Paramet-
ric data were analysed using one-way analysis of vari-
ance. All p values were two-sided, and p values less than
0.05 were considered statistically significant.
Results
Oxidative stress alters cellular bioenergetics in RASFC and
HUVEC in vitro
Previous studies by our group demonstrated altered cel-
lular bioenergetics in RASFC in the presence of hypoxia
[14], and we have also demonstrated high oxidative
stress in the inflamed synovium [22]. Therefore, in this
study, we further investigated whether oxidative stress in
the inflamed joint is involved in metabolic reprogram-
ming of RASFC and HUVEC. Figure 1a demonstrates
representative OCR and ECAR profiles before and after
injections of oligomycin, FCCP, antimycin A and 2-DG
in basal and 4-HNE-stimulated RASFC. We show, for
the first time to our knowledge, that inhibition of OCR
following 4-HNE-induced oxidative stress was associated
with a shift in RASFC metabolism towards glycolysis. 4-
HNE reduced basal mitochondrial respiration (p < 0.05), par-
alleled by a reduction in maximal mitochondrial respiration
(p < 0.001), ATP synthesis (p= 0.1) and reserve capacity (p <
0.01) (Fig. 1b). This metabolic reprogramming was further
accompanied by increased levels of basal glycolysis (p < 0.01),
glycolytic capacity (p < 0.01) and glycolytic reserve (p = 0.
2) in RASFC subjected to oxidative stress (Fig. 1b).
Representative HUVEC OCR and ECAR profiles be-
fore and after injections of oligomycin, FCCP, antimy-
cin A and 2-DG are shown on Fig. 2a. Similarly to
RASFC, 4-HNE inhibited basal mitochondrial respir-
ation, maximal mitochondrial respiration, ATP synthesis
and reserve capacity (all p < 0.01) with concomitant eleva-
tion of basal glycolysis (p < 0.01) and glycolytic reserve (p
< 0.05) in HUVEC exposed to oxidative stress (Fig. 2b).
Examination of mitochondrial mutagenesis and activity of
enzymes of mitochondrial OXPHOS complexes under 4-
HNE-induced oxidative stress
We have previously shown that increased mtDNA muta-
tion frequency and mitochondrial dysfunction in the RA
joint were strongly associated with synovial inflammation
and hypoxia [27, 28]. We have also reported, at a func-
tional level, induction of pro-angiogenic responses of
endothelial cells in the presence of oxidative stress [29]. In
the present study, we assessed the frequency of mtDNA
mutations and mitochondrial dysfunction in RASFC sub-
jected to 4-HNE. We observed increases in ROS produc-
tion and mtDNA point mutations in RASFC in the
presence of 4-HNE compared with basal cells (p < 0.001
and p = 0.06, respectively) (Fig. 3a). 4-HNE protein
adduction may alter protein activity; therefore, we next ex-
amined the activity of the individual proteins of mitochon-
drial OXPHOS complexes I–V. 4-HNE significantly
reduced the activity of complex III by 8% and complex IV
by 70% compared with basal values (both p < 0.01). Lower
enzymatic activity following 4-HNE stimulation was also
detected for complex I by 9%, complex II by 22% and
complex V by 12% (all p = 0.2) (Fig. 3b).
In vitro secretion of pro-angiogenic and pro-inflammatory
mediators under oxidative stress conditions
Because we found a close association of redox state with
energy metabolism in RASFC, we next examined the ef-
fect of oxidative stress on angiogenic and inflammatory
mediators from RASFC. Figure 4 demonstrates increased
VEGF immunofluorescence staining in RASFC cultured
in the presence of 4-HNE compared with the basal cells.
In addition, 4-HNE significantly increased secretion of
key pro-inflammatory and pro-angiogenic mediators
compared with basal RASFC (VEGF, Ang2, bFGF, IL-8
[all p < 0.05], PDGF-B, RANTES, ICAM [all p < 0.01]).
These findings, along with our previously published in
vitro study showing TNF-α-induced mitochondrial dys-
function [28], further support the concept of the com-
plex interplay between oxidative damage, oxygen
metabolism and angiogenesis in RA. Therefore, we next
determined angiogenic in vivo responses following TNFi
in 15 patients with RA at baseline (T0) and 3 months
after the commencement of biologic treatment (T3).
Additional file 1: Figure S1A shows changes of
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macroscopic vascularity and ST expression of VEGF,
Ang2 and Tie2 from T0 to T3. Additional file 1: Figure
S1B graphically illustrates decreases in ST VEGF (p = 0.
1), Ang2 (p < 0.005) and Tie2 (p < 0.005) after TNFi
therapy.
Oxidative stress-activated RASFC promote pro-angiogenic
mechanisms in HUVEC
RASFC are known to be strongly involved in regulating
pathological angiogenesis in the inflamed joint [30].
Therefore, we next examined if the observed alterations in
cellular bioenergetics and pro-inflammatory processes in
RASFC in response to oxidative stress could subsequently
influence pro-angiogenic mechanisms in HUVEC. We stim-
ulated RASFC in the presence or absence of 4-HNE and har-
vested the supernatants, termed conditioned media. Fig. 5a
demonstrates the effect of basal or 4-HNE RASFC-CM on
invasion, the formation of tube-like structures and migration
of HUVEC. Figure 5b graphically illustrates markedly in-
duced invasion (p < 0.001), proliferation (p < 0.05),
number of formed tube-like structures (p < 0.001), cell
migration across the wound (p < 0.001) and secretion
of Ang2 and PDGF-B (both p values < 0.05) in
HUVEC in response to basal or 4-HNE RASFC-CM.
To confirm that the increase in pro-angiogenic re-
sponses of HUVEC was due to oxidatively activated
RASFC and not to residual 4-HNE present in the CM,
additional experiments were performed, consisting of
RPMI 1640 media supplemented with 4-HNE (0.25 μM;
4-HNE RPMI 1640 control), which would be at the same
concentration of 4-HNE in the 10% RASFC-CM. A sig-
nificant increase in invasion (p < 0.001), number of formed
Fig. 1 Bioenergetic metabolism in primary rheumatoid arthritis synovial fibroblast cells (RASFC) subjected to 4-hydroxy-2-nonenal (4-HNE)-induced
oxidative stress. a Representative oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) Seahorse analyser profiles before and
after injections of oligomycin, trifluorocarbonylcyanide phenylhydrazone (FCCP), antimycin A and 2-deoxyglucose (2-DG) in RASFC in the presence
and absence of 4-HNE. b Bar graphs demonstrate quantification of basal mitochondrial (Mt) respiration, maximal Mt respiration, adenosine
triphosphate (ATP) synthesis, reserve capacity, basal glycolysis, glycolytic capacity and glycolytic reserve in RASFC (n = 5) subjected to oxidative
stress. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001, significant differences from basal level
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tube-like structures (p < 0.01) and cell migration across
the wound (p < 0.001) in HUVEC in response to 4-HNE
RASFC-CM compared with 4-HNE RPMI 1640 control
media further supports the direct effect of 4-HNE on
RASFC-induced angiogenesis in the inflamed joint (Add-
itional file 2: Figure S2).
Association between ST angiogenesis, oxidative stress
and bioenergetics
Finally, the correlation of angiogenic factors with previ-
ously assessed markers of oxidative stress and metabol-
ism in this patient cohort was examined [14]. ST 4-HNE
expression was associated with increased expression of
VEGF (r = 0.63; p = 0.015) and Tie2 (r = 0.56; p = 0.029),
GAPDH (r = 0.60; p = 0.03) and with reduced levels of
ATP5B (p = − 0.52, p = 0.017). Furthermore, representative
immunofluorescence images demonstrating co-localisation
of 4-HNE with angiogenic factors (VEGF, Ang2, Tie2)
, as well as with mitochondrial (ATP5B) and glycolytic
(GAPDH, PKM2, GLUT1) proteins, is demonstrated in
Fig. 6. Additional file 3: Figure S3 and Additional file 4:
Figure S4 show single images of VEGF, Ang2, Tie2,
GAPDH, PKM2, GLUT1 and ATP5B (all in red), single
images of 4-HNE immunofluorescence (in green), as well
as single images of DAPI (in blue), along with their con-
trols with isotype-matched antibodies.
Discussion
In this study, we demonstrate, for the first time to our
knowledge, that oxidative stress reprograms cellular bio-
energetics of RASFC and HUVEC by downregulating
OXPHOS and promoting glycolysis. This change was
Fig. 2 Bioenergetic metabolism in human umbilical vein endothelial cells (HUVEC) subjected to 4-hydroxy-2-nonenal (4-HNE)-induced oxidative
stress. a Representative oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) Seahorse analyser profiles before and after
injections of oligomycin, trifluorocarbonylcyanide phenylhydrazone (FCCP), antimycin A and 2-deoxyglucose (2-DG) in HUVEC in the presence and
absence of 4-HNE. b Bar graphs demonstrate quantification of basal mitochondrial (Mt) respiration, maximal Mt respiration, adenosine
triphosphate (ATP) synthesis, reserve capacity, basal glycolysis, glycolytic capacity and glycolytic reserve in HUVEC (n = 3) subjected to oxidative
stress. Data are presented as mean ± SEM. *p < 0.05 and **p < 0.01, significant differences from basal level
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reflected by a decrease in mitochondrial maximal and
ATP-linked respiration and reserve capacity, whereas
glycolytic capacity and glycolytic reserve were elevated
in the presence of 4-HNE. A bioenergetic switch was
coupled with higher ROS production and mtDNA
mutations, in addition to the reduced enzymatic activity
of mitochondrial complexes III and IV. Oxidative stress
also induced secretion of pro-angiogenic and pro-
inflammatory mediators by RASFC. CM from 4-HNE-
activated RASFC potentiated pro-angiogenic mecha-
nisms in HUVEC, as reflected by elevated cell invasion,
proliferation, migration, the formation of tube-like struc-
tures and secretion of pro-angiogenic mediators. In vivo
co-expression of angiogenic markers, oxidative damage
and oxygen metabolism was demonstrated in ST. Finally,
a decrease in ST angiogenesis was observed in patients
with RA following TNFi therapy.
Hypoxia is a fundamental metabolic change in ST of RA
associated with elevated mitochondrial ROS production
and lipid peroxidation. Covalent modifications of mtDNA,
lipids and proteins by 4-HNE have been reported to com-
promise mitochondrial integrity and function, including re-
spiratory metabolism, protein transportation, mitochondrial
dynamics and quality control through fission, fusion and
mitophagy [16]. We have previously shown that increased
mtDNA mutation frequency and mitochondrial dysfunc-
tion in the RA joint correlated with greater hypoxia, oxida-
tive stress, vascularity and pro-inflammatory cytokines [27,
28]. Our present in vitro findings using RASFC further
demonstrate high susceptibility of the mitochondrial gen-
ome to oxidative damage. A mitochondrial random muta-
tion capture assay was used to quantify the frequency of
random mitochondrial point mutations in RASFC follow-
ing 4-HNE stimulations. This methodology relies on single-
Fig. 3 Mitochondrial mutagenesis and activity of enzymes of mitochondrial oxidative phosphorylation (OXPHOS) complexes under 4-hydroxy-2-nonenal
(4-HNE)-induced oxidative stress. a Bar graphs demonstrate increased production of reactive oxygen species (n= 7), paralleled by the greater frequency of
mitochondrial DNA mutation (n= 5) in primary rheumatoid arthritis synovial fibroblast cells (RASFC) in response to 4-HNE. b Activity of mitochondrial
OXPHOS complexes I–V in the presence of 4-HNE. 4-HNE reduces the activity of complex I by 9%, complex II by 22%, complex III by 8%, complex IV by
70% and complex V by 12% (all complexes measured in triplicate). For each complex, results are graphically demonstrated as the percentage of enzymatic
activity in the presence of 4-HNE relative to the percentage of basal activity. Data is represented as Mean ± SEM, **p<0.01; ***p<0.001 significantly different
to basal
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molecule amplification to screen a large number of mtDNA
molecules for the presence of unexpanded mutations that
may appear following oxidative stress. Elevated mitochon-
drial mutagenesis detected in RASFC exposed to oxidative
stress supports the evidence of the mutagenic nature of 4-
HNE. 4-HNE-guanine adducts have been detected in the
p53 tumour suppressor gene in a human lymphoblastoid
cell line, causing gene mutation and affecting cell cycle ar-
rest, apoptosis, DNA repair and differentiation [31]. Ele-
vated mtROS levels are considered a primary source of
mitochondrial mutagenesis. Our findings show high pro-
duction of ROS by RASFC exposed to 4-HNE, indicating
the ability of 4-HNE to further exacerbate ROS generation,
thereby creating the vicious cycle of oxidative stress-
induced alteration to the mitochondrial genome.
We investigated if mitochondrial genome instability
driven by products of lipid peroxidation is accompanied
by defects in respiratory metabolism. The two major en-
ergy pathways were measured to find that in the
presence of 4-HNE, RASFC and HUVEC switched their
bioenergetic profile from OXPHOS to anaerobic glycoly-
sis to respond to an increased energy demand. This was
coupled with reduced maximal and ATP-linked respir-
ation and reserve capacity, in contrast to elevated glyco-
lytic capacity and glycolytic reserve. In addition, the
enzymatic activities of mitochondrial complexes were
decreased by oxidative stress. This compensatory reli-
ance on anaerobic glycolysis may provide a short-term
solution; however, prolonged dependence may result in a
severe energy deficiency that ultimately creates a bio-
energetic crisis, most likely supporting abnormal angio-
genesis, cellular invasion and pannus formation.
Our data are consistent with previous studies demon-
strating 4-HNE-induced mitochondrial respiration defi-
ciency in cardiac and small airway epithelial cells [32,
33]. Inhibition of mitochondrial respiration following 4-
HNE stimulation could be due to reduced functionality
from 4-HNE protein-adducts of proteins associated with
Fig. 4 4-Hydroxy-2-nonenal (4-HNE) induces pro-angiogenic and pro-inflammatory mechanisms in primary rheumatoid arthritis synovial fibroblast
cells (RASFC). Increased vascular endothelial growth factor (VEGF) immunofluorescence in RASFC subjected to 4-HNE compared to the basal cells
and quantification of VEGF, angiopoietin 2 (Ang2), basic fibroblast growth factor (bFGF), interleukin (IL)-8, platelet-derived growth factor subunit B
(PDGF-B), regulated on activation, normal T cell expressed and secreted (RANTES), intercellular adhesion molecule (ICAM) in RASFC supernatants
(n = 7) following cell culture with 4-HNE. Data are presented as mean ± SEM. *p < 0.05 and **p < 0.01, significant differences from basal level. Red
= VEGF; blue = 4′,6-diamidino-2-phenylindole–; magnification of photomicrographs × 40
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the ETC and ATP synthase, or it could be due to a di-
minished ability of RASFC to detoxify 4-HNE because
this process requires energy. A study using a proteomic
approach identified several 4-HNE-modified mitochon-
drial proteins in cardiac mitochondria from mice treated
with doxorubicin, one of the most widely used chemo-
therapeutic drugs [34]. Identified proteins were related
to mitochondrial energy metabolism, including subunits
of the ETC such as NDUFS2 (complex I), SDHA (com-
plex II) and ATP5B (complex V), as well as dihydroli-
poamide dehydrogenase, a component of the TCA cycle.
Subsequently, 4-HNE adduction reduced enzymatic ac-
tivity of the mitochondrial proteins, declined OCR and
increased ECAR profiles. Other studies identified the 4-
HNE modification of proteins involved in metabolism,
adhesion, cytoskeletal reorganisation and anti-oxidation
in human platelets [35].
In this study, increased secretion of pro-angiogenic
and pro-inflammatory mediators by RASFC was ob-
served in the response to 4-HNE. Furthermore, RASFC-
CM potentiated pro-angiogenic processes of HUVEC,
including endothelial cell invasion, proliferation and
migration; the formation of tube-like structures; and se-
cretion of pro-angiogenic mediators. These findings pro-
vide evidence for direct and indirect pro-angiogenic
effects in response to 4-HNE within the inflamed joint.
Our findings are in agreement with other studies show-
ing 4-HNE-induced expression of COX-2, IL-1β, IL-18
and NF-κB and activation of the NLRP3 inflammasome
[36–38]. In inflammatory conditions, oxidative stress
may mediate angiogenic mechanisms through VEGF-
independent pathways involving ROS-induced lipid oxi-
dation. Redox upregulated angiogenic responses of
RASFC observed in our study were also reported by
others in HUVEC, keratinocytes and epithelial lung and
retinal cells [29, 39, 40]. Blocking glycolysis with glyco-
lytic inhibitors reduces pro-inflammatory responses of
RASFC and HUVEC as well as the severity of arthritis in
K/BxN mice [7, 14]. Furthermore, hypoxic activation of
the glycolytic enzyme glucose-6-phosphate isomerase
up-regulated VEGF secretion, proliferation and invasion
in RASFC and HUVEC [41]. Several glycolytic proteins,
Fig. 5 Effects of primary rheumatoid arthritis synovial fibroblast cell (RASFC)-conditioned media on angiogenic responses of human umbilical vein
endothelial cells (HUVEC). a Representative images demonstrating invasion, the formation of tube-like structures and migration of HUVEC cultured
in the presence of basal or 4-hydroxy-2-nonenal (4-HNE)-supplemented conditioned media. Magnification × 10 of photomicrographs demonstrating
invasion, tube formation (arrows indicate connecting branches) and cell migration. b Bar graphs demonstrate an increase in the number of invading,
proliferating and migrating HUVEC, a higher number of connecting branches formed between HUVEC, and greater angiopoietin 2 (Ang2) and platelet-
derived growth factor subunit B (PDGF-B) release from HUVEC exposed to 4-HNE-supplemented conditioned media (n = 6). Data are presented as
mean ± SEM. *p < 0.05 and ***p < 0.001, significant differences from basal level. hpf High-power field
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including PKM2, GAPDH, fructose bisphosphate aldol-
ase A (aldolase A) and phosphoglycerate kinase 1 have
been shown to be adducted by lipid electrophiles [42–
44]. Subsequently, this covalent modification is sug-
gested to impair glucose metabolism and result in the
accumulation of glycolytic intermediates. This is consist-
ent with studies showing significant increases in lactate
levels and ECAR by human platelets cultured with 4-
HNE [35] and increased 18F-fludeoxyglucose uptake and
glycolytic metabolism by oxidised low-density lipopro-
tein (oxLDL) through upregulation of GLUT1 expres-
sion and hexokinase activity [45]. This response was
mediated by hypoxia-inducible factor 1α activation and
dependent on ROS overproduction. In turn, this meta-
bolic effect of oxLDL was completely abrogated by Src
(PP2) and phosphatidylinositol-3 kinase inhibitors, sup-
porting the regulatory role of this pathway in glucose
metabolism and immune cell activation.
TNF-α promotes angiogenesis and may regulate capil-
lary formation via VEGF, Ang1 and Ang2 and their recep-
tors. In this study, we investigated whether TNFi therapy
alters levels of angiogenic markers 3 months after the
commencement of treatment. Following TNFi treatment,
reduced ST expression of VEGF, Tie2 receptor and its
Ang2 ligand was observed, which further supports the
strong link between angiogenesis and TNF-α. These findings
are in agreement with those of other studies showing re-
duced expression of angiogenic markers and endothelial cell
activation following TNFi treatment [46, 47]. Additionally,
previous studies have demonstrated positive effects of TNFi,
including etanercept and infliximab, on oxidative
damage in RA, showing significantly reduced serum
and urinary levels of oxidative DNA damage and lipid
peroxidation with corresponding decreases in DAS28
score following TNFi therapy [48, 49]. Similarly, the
serum level of oxidative stress markers was remark-
ably suppressed in patients with RA treated with toci-
lizumab IL-6-blocking therapy compared with those
treated with anti-TNF antibodies [50].
Conclusions
In this study, we examined the interplay of synovial
cellular bioenergetics, oxidative stress and angiogen-
esis in RA. We have demonstrated that oxidative stress
Fig. 6 Synovial tissue (ST) angiogenesis, oxidative stress and cellular bioenergetics. To support the concept that oxidative stress, angiogenesis and
energy metabolism are interconnected processes that co-exist during the inflammation milieu, double-immunofluorescence staining was
performed. ST slides were co-incubated with primary mouse antibody against human 4-hydroxy-2-nonenal (4-HNE) and with primary rabbit
antibodies against angiogenic factors (vascular endothelial growth factor [VEGF], angiopoietin 2 [Ang2], tyrosine kinase receptor [Tie2]), glycolytic
proteins (glyceraldehyde 3-phosphate dehydrogenase [GAPDH], pyruvate kinase isozyme 2 [PKM2], glucose transporter 1 [GLUT1]) and a
mitochondrial marker (adenosine triphosphate synthase subunit β [ATP5B]). Representative merged immunofluorescence images demonstrate
examples of co-localisation (yellow) of 4-HNE with VEGF, Ang2, Tie2, GAPDH, PKM2, GLUT1 and ATP5B. Cells stained green are positive for 4-HNE
only; cells stained red are positive only for VEGF, Ang2, Tie2, GAPDH, PKM2, GLUT1 and ATP5B. Arrows indicate examples of co-localisation.
Magnification of photomicrographs × 20, insets show high-power magnification of co-localisation. Representative images show single
immunofluorescence of 4-HNE, VEGF, Ang2, Tie2, GAPDH, PKM2, GLUT1 and ATP5B along with their controls. Isotype-matched antibodies are
shown in Additional file 3: Figure S3 and Additional file 4: Figure S4
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switched bioenergetic profiles from OXPHOS to anaer-
obic glycolysis in response to an increased energy demand
in the inflamed joint. This creates a bioenergetic crisis that
may contribute to dysfunctional angiogenesis to further
promote inflammatory mechanisms in RA. In addition,
ST upregulation of the angiopoietin/Tie2 system can be
altered following TNFi therapy.
Additional files
Additional file 1: Figure S1. Synovial tissue expression of angiogenic
markers in patients with RA. A Representative images demonstrating
macroscopic vascularity and ST VEGF, Ang2 and Tie2 immunostaining at
baseline (T0) and 3 months after the commencement of biologic
treatment (T3). Magnification of photomicrographs × 20. B Baseline and
3 months post-TNFi quantification of ST VEGF, ST Ang2 and ST Tie2 in
patients with RA (n = 15). Data are presented as mean ± SEM. *p < 0.05;
**p < 0.01. (TIF 5466 kb)
Additional file 2: Figure S2. Effects of oxidatively activated RASFC on
angiogenic responses of HUVEC. To confirm that the increase in pro-
angiogenic responses of HUVEC is due to oxidatively activated RASFC and not
residual 4-HNE present in the conditioned media, HUVEC were cultured in the
presence of RPMI 1640 media supplemented with 4-HNE (0.25 μM; 4-HNE
RPMI 1640 control), which was at the same concentration of 4-HNE in the
10% RASFC conditioned media. Representative images and bar graphs
demonstrate higher invasion, greater number of formed tube-like structures
and greater cell migration across the wound in HUVEC in response to 4-HNE
RASFC-conditioned media (4-HNE RASFC-CM; n = 6) than in response to
4-HNE RPMI 1640 control. Data are presented as mean ± SEM. **p< 0.01 and
***p< 0.001, representing significant differences from control. Magnification of
photomicrographs demonstrating invasion, tube formation (arrows show
connecting branches) and cell migration × 10. (TIF 8263 kb)
Additional file 3: Figure S3. ST angiogenesis and oxidative stress.
Representative images of immunofluorescent staining between markers
of angiogenesis and 4-HNE in inflamed synovial tissue of patients with
RA: VEGF, Ang2 and Tie2 (red); 4-HNE (green); DAPI (blue); and merged
images (yellow). Insets show negative control staining with
isotype-matched antibodies. Magnification of photomicrographs × 20.
(TIF 9793 kb)
Additional file 4: Figure S4. ST cellular bioenergetics and oxidative
stress. Representative immunofluorescence images show co-localisation
of the oxidative stress marker 4-HNE with glycolytic proteins (GAPDH,
PKM2, GLUT1) and a mitochondrial marker (ATP5B) in inflamed ST of
patients with RA: GAPDH, PKM2, GLUT1, and ATP5B (red); 4-HNE (green);
DAPI (blue); merged images (yellow). Insets show negative control staining
with isotype-matched antibodies. Magnification of photomicrographs ×
20. (TIF 9536 kb)
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